List view / Grid view
17 December 2015 | By Victoria White
The FDA has approved Basaglar for the treatment of adult and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus...
10 December 2015 | By Victoria White
Faster-acting insulin aspar is an investigational mealtime insulin developed by Novo Nordisk for the control of blood sugar levels in adults with type 1 and type 2 diabetes...
4 December 2015 | By Victoria White
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes...
New data from a completed Phase 3 trial show Lilly’s Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering haemoglobin A1c (A1C) from baseline after 24 weeks of treatment.
2 December 2015 | By Victoria White
Novo Nordisk has released new data that shows Victoza (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose cotransporter 2 inhibitors...
18 November 2015 | By Victoria White
Merck and Novapharm have announced a joint venture in Algeria to produce Merck’s diabetes and high blood pressure treatments for the Algerian market...
16 November 2015 | By Victoria White
New research shows socio-cultural factors including time pressure, commuting time and where you live play significant roles in diabetes vulnerability...
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
5 November 2015 | By Victoria White
Sanofi and Hanmi have entered a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments...
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
25 September 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with exenatide in 813 people with type 2 diabetes...
17 September 2015 | By Victoria White
The DUAL V trial evaluated the efficacy and safety of Xultophy compared to insulin glargine U100 in adults with type 2 diabetes...
16 September 2015 | By Victoria White
Results from a new study showed different perceptions of control among physicians and patients that may lead to suboptimal type 2 diabetes management...
16 September 2015 | By Victoria White
Findings from the LIRA-LIXI trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in type 2 diabetes...
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
